Navelbine (N), leucovorin (L), and fluorouracil (5-FU) (FLN) for triple-negative metastatic breast cancer (TNBC)

1127 Background: TNBC (ER, PR, HER2 negative) pts can be treated with conventional chemotherapy only. The combination of 5- FU (350 mg/m2 iv bolus day 1 to 3), L (100 mg/m2 iv day 1 to 3) and N (20–25 mg/m2 bolus on day 1 and 3) every 3 weeks is an active regimen in metastatic breast cancer (MBC) (Nole et al., Ann Oncol 1997). Methods: Among 137 consecutive MBC pts routinely treated at our Institution with the FLN regimen since 1999, 26 (19%) had TNBC. Median age was 61 yrs, prior adjuvant CT: 88%, one line of CT for MBC: 42%, Visceral involvement: 80%, >2 metastatic sites: 52%. Results: Efficacy data of FLN regimen are reported in Table 1. Response rate, TTF and OS among 105 evaluable non-TNBC pts treated during the same period with FLN were 48%, 7 mos and 19 mos, respectively. Among the 26 TNBC pts, neutropenia was the most frequent toxicity (NCI-CTCv2 grade IV in 32% of pts), with neutropenic fever in 3 cases (one toxic death). Nausea, vomiting and anorexia were mild to moderate in 35% of pts. Grade II...